The information contained in this website has been developed by Arcutis Medical Affairs and is intended for US healthcare professionals (HCPs) only.
Explore our ongoing and completed clinical trials below.
Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis
Topical roflumilast cream (ARQ-151) atopic dermatitis study in pediatric patients (INTEGUMENT-PED)
Completed
Topical roflumilast foam (ARQ-154) phase 3 seborrheic dermatitis study (STRATUM)
Topical roflumilast foam (ARQ-154) phase 3 scalp and body psoriasis study (ARRECTOR)
Topical roflumilast foam (ARQ-154) phase 2b scalp and body psoriasis study
Topical roflumilast foam (ARQ-154) phase 2 seborrheic dermatitis phase 2 study
Topical roflumilast foam (ARQ-154) phase 2 seborrheic dermatitis long-term safety study
Topical roflumilast cream (ARQ-151) phase 3 plaque psoriasis study (DERMIS-2)
Topical roflumilast cream (ARQ-151) phase 3 plaque psoriasis study (DERMIS-1)
Topical roflumilast cream (ARQ-151) phase 3 plaque psoriasis open-label extension (DERMIS-OLE)
You are now leaving the Arcutis Medical Affairs website. Arcutis Biotherapeutics is not responsible for the content on these third-party websites.